UPSC Margin
NotesTestsDaily CACSAT
UPSC Margin

Analytical concept notes, daily current affairs, and mock tests for serious UPSC aspirants.

Learn

  • Notes
  • Daily Current Affairs
  • Mock Tests
  • CSAT
  • Strategy Guide

Resources

  • About
  • Pricing
  • Blog
  • Contact
  • RSS Feed

Support

  • Help & FAQ
  • Privacy Policy
  • Terms of Use
  • Telegram Community

© 2026 UPSC Margin. All rights reserved.

Operated by Satyam Raj · hello@upscmargin.com

Back to Notes
Science & TechFree till Sep 9

Gene Editing and CRISPR: Medical and Ethical Dimensions

July 19, 2026

TOPIC CLASSIFICATION

Subject: Science & Technology Sub-area: Biotechnology Prelim PYQ Trend: Moderate (concept questions, Nobel Prize related) Mains Relevance: GS-3 (Science & Technology, Ethics)

EXAMINER REASONING

CRISPR-Cas9 won the Nobel Prize in Chemistry (2020), making it a high-probability UPSC topic. The examiner tests: (a) technical understanding — how CRISPR works, components (Cas9, guide RNA, PAM sequence); (b) applications — gene therapy, agriculture (GM crops), disease models; (c) ethical dimensions — germline editing (He Jiankui case), designer babies, eugenics concerns; (d) regulatory framework in India — GEAC, DBT guidelines. Expect comparative questions with other gene-editing tools (ZFN, TALEN) and ethical dilemma questions.

Core Concept

What is Gene Editing? Gene editing is a type of genetic engineering in which DNA is inserted, deleted, modified, or replaced in the genome of a living organism using engineered nucleases (molecular scissors).

CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats):

  • Discovery: Emmanuelle Charpentier and Jennifer Doudna (Nobel Prize 2020)
  • Components: Cas9 enzyme (cuts DNA) + guide RNA (gRNA — targets specific DNA sequence) + PAM sequence (protospacer adjacent motif — required for cutting)
  • How It Works: gRNA guides Cas9 to target DNA → Cas9 cuts both strands → cell's natural repair mechanisms (NHEJ or HDR) are used to modify the gene
  • Advantages: Cheaper, faster, more precise than earlier methods (ZFN, TALEN)

Other Gene Editing Tools:

ToolMechanismPrecision
ZFNsZinc finger proteins + FokI nucleaseModerate
TALENsTAL effector + FokI nucleaseHigh
CRISPR-Cas9

Read Next

More in Science & Tech

5G and 6G Technology: Features and India's Rollout

Artificial Intelligence: Applications, Ethics, and India's AI Strategy

Artificial Intelligence is reshaping global economies, and India is positioning itself as a significant AI player. This note covers AI applications in healthcare, agriculture, governance, and defence, ethical concerns including algorithmic bias, privacy, and job displacement, and India's AI strategy — INDIAai platform, NITI Aayog's national AI strategy (#AIforAll), the Bhashini language AI initiative, and the Global Partnership on AI (GPAI).

AstroSat and India's Space Observatories

RNA-guided Cas9
Very High
Base EditingCas9 variant (nickase) + deaminaseSingle-base precision
Prime EditingCas9 nickase + reverse transcriptase + pegRNASearch-and-replace

Medical Applications:

  • Sickle Cell Disease: Casgevy (exagamglogene autotemcel) — first CRISPR therapy approved (UK, US, 2023)
  • Cancer Immunotherapy: CRISPR-modified CAR-T cells (clinical trials in India — IIT Bombay)
  • HIV: CCR5 gene disruption to mimic natural HIV resistance (Berlin patient → London patient)
  • Thalassaemia: Similar to sickle cell — reactivating fetal haemoglobin
  • Cystic Fibrosis: Correcting CFTR mutations (early trials)
  • Universal Donor Organs: CRISPR-modified pig organs for xenotransplantation (first US trial 2024)

Ethical Dimensions:

  • Germline Editing: Heritable changes — banned in most countries (UNESCO, WHO guidelines)
  • He Jiankui Case (2018): Chinese scientist who created first gene-edited babies (Lulu and Nana) — CCR5 modified, convicted
  • Designer Babies: Enhancement vs therapy — slippery slope
  • Equity: Therapy access — likely expensive, creating genetic divide
  • Ecological: Gene drives (altering entire wild populations — mosquitoes for malaria control)

Key Facts

  1. CRISPR-Cas9 awarded Nobel Prize in Chemistry 2020 (Charpentier, Doudna)
  2. First CRISPR therapy (Casgevy): Approved December 2023 for sickle cell disease and β-thalassaemia
  3. India's regulatory body: GEAC (Genetic Engineering Appraisal Committee) under MoEFCC — reviews gene-editing experiments
  4. DBT Guidelines 2022: "Guidelines for Safety Assessment of Genome Edited Plants" — differentiated SDN-1, SDN-2, SDN-3 modifications
  5. SDN-1 (Site-Directed Nuclease 1): No foreign DNA — treated equivalent to conventional mutagenesis (exempt from GM regulation)
  6. India's status: Phase 1 clinical trials for CRISPR-based sickle cell therapy at AIIMS Delhi (2024)
  7. Moratorium on germline editing — WHO advisory committee, India follows ICMR guidelines
  8. CRISPR applications: Over 40+ clinical trials globally for various diseases

PYQ Trend

YearQuestionTopic
2024"Discuss the ethical issues associated with gene editing"Ethics of gene editing
2023"What is CRISPR-Cas9? Explain its potential applications"Technology
2022"Distinguish between somatic and germline gene therapy"Types of therapy
2021"Examine the regulatory framework for GM crops in India"GM regulation
2020"How can biotechnology help in tackling genetic diseases?"Medical applications

Statement Elimination Guide

  • "CRISPR can cure all genetic diseases" — only specific monogenic disorders currently; complex diseases (cancer, diabetes) are polygenic
  • "Gene editing is banned in India" — SDN-1 genome editing is exempt from GM regulation; clinical trials allowed with oversight
  • "Germline editing is heritable and ethically controversial" — correct, changes pass to future generations
  • "CRISPR-Cas9 works on all organisms identically" — delivery mechanisms, PAM sequence requirements vary
  • "The He Jiankui case raised global concerns about gene editing ethics" — correct

Current Affairs Hook

  • 2025: US FDA approves CRISPR therapy for sickle cell disease; India's trials at AIIMS continue
  • 2026: Global Genome Editing Summit (WHO) — new guidelines on germline editing
  • India Specific: GEAC approval of SDN-1 genome edited plants (DMH-11 mustard remains contentious)
  • New Tech: CRISPR 2.0 — epigenetic editing, base editors, prime editing; CRISPR diagnostics (SHERLOCK, DETECTR for disease detection)
  • Xenotransplantation: First CRISPR-edited pig heart transplanted to human patient (2024)

Interlinkages

  • Ethics (GS-4): Germline editing ethics, eugenics, informed consent, distributive justice
  • Agriculture (GS-3): GM crops, GEAC regulation, SDN-1 vs transgenic debate
  • Health (GS-2): Rare diseases policy, affordable therapies, clinical trial regulation
  • Environment (GS-3): Gene drives for vector control (malaria), ecological risks
  • IPR (GS-3): Patenting of CRISPR-Cas9 (Broad Institute vs UC Berkeley battle)
  • International Relations (GS-2): Cartagena Protocol on Biosafety, WHO guidelines

Common Mistakes

  1. Confusing gene editing with genetic modification — gene editing (site-directed) is distinct from transgenic modification (introducing foreign genes)
  2. Assuming CRISPR is the only gene-editing tool — ZFNs, TALENs, base editing, prime editing also exist
  3. Not distinguishing somatic vs germline — somatic (non-heritable, less controversial) vs germline (heritable, banned)
  4. Ignoring India's regulatory stance on SDN-1 — DBT Guidelines 2022 exempt SDN-1 from GM regulation — a key UPSC point
  5. Over-simplifying ethical issues — need to balance therapeutic potential (somatic) with caution (germline)

Revision Snapshot

CRISPR — Quick Recap
├── Components: Cas9 + gRNA + PAM | Nobel 2020
├── Types: Somatic (therapy) vs Germline (heritable, banned)
├── Medical: Sickle cell | Thalassaemia | Cancer | HIV | Xenotransplant
├── India: AIIMS trials | DBT SDN-1 guidelines | GEAC oversight
└── Ethics: Designer babies | Equity | Gene drives | He Jiankui

Source Notes

  • DBT — Guidelines for Safety Assessment of Genome Edited Plants (2022)
  • ICMR — National Ethical Guidelines for Biomedical Research
  • WHO — Human Genome Editing Report (2021)
  • Nature/Science Journals — CRISPR updates
  • AIIMS — Annual Research Reports (CRICS trial)
  • Nobel Prize Committee — CRISPR-Cas9 (2020)